Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis
American Journal of Kidney DiseasesPublished 28 January 2004
Przemysław Rutkowski, Leszek Tylicki, Marcin Renke, Grzegorz Korejwo, Zbigniew Zdrojewski, Piotr Rutkowski
Citations56
SJR quartileQ1
SJR score3.02
SNIP2.94
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The study shows that combination therapy with very small doses of losartan and benazepril was more effective in reducing proteinuria than greater doses of either agent in monotherapy, and this greater antiproteinuric efficacy was independent of changes in BP.
Abstract
The study shows that combination therapy with very small doses of losartan and benazepril was more effective in reducing proteinuria than greater doses of either agent in monotherapy, and this greater antiproteinuric efficacy was independent of changes in BP.
Keywords
Medicine
New England Journal of MedicineEffects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
7,484 Citations2001Barry M. Brenner, Mark E. Cooper +8 more
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
New England Journal of MedicineRenoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
5,920 Citations2001Edmund J. Lewis, Lawrence G. Hunsicker +8 more
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
New England Journal of MedicineThe Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
5,377 Citations1993Edmund J. Lewis, Lawrence G. Hunsicker +2 more
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
New England Journal of MedicineEffect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency
1,765 Citations1996Giuseppe Maschio, Daniele Alberti +7 more
A study to determine the effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases.
Designing Clinical Research
1,764 Citations2006Stephen B. Hulley
BASIC INGREDIENTS Getting Started: The Anatomy and Physiology of Clinical Research Stephen B. Hulley and Steven R. Cummings Getting Ready to Estimate Sample Size: Hypotheses and Underlying Principles Warren S. Browner, Thomas B. Newman, and Stephen R.Hulley Estimating Sample Size and Power: Applications and Examples.
The LancetRETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
977 Citations2003Naoyuki Nakao, Ashio Yoshimura +4 more
Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive nondi diabetic renal disease need to be researched.
The LancetRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
897 Citations1999Piero Ruggenenti, Annalisa Perna +7 more
In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria, and the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been instratum 2.
TechnometricsCross-Over Trials in Clinical Research
765 Citations1994
The cross over trials in clinical research is universally compatible with any devices to read, and is available in the book collection an online access to it is set as public so you can get it instantly.
ACC Current Journal ReviewEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
511 Citations2002B. M. Brenner, M. E. Cooper +1 more
Kidney InternationalUrinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies
435 Citations1998Piero Ruggenenti, on behalf of the “Gruppo Italiano di Studi Epidemiologici in Nefrologia”(GISEN) +4 more
In chronic nephropathies proteinuria is the best independent predictor of both disease progression and ESRF, and mean UProt and mean arterial pressure and systolic blood pressure during follow-up were the only time-dependent covariates that significantly correlated with delta GFR.
Kidney InternationalIs the antiproteinuric effect of ACE inhibition mediated by intereference in the renin-angiotensin system?
296 Citations1994Ron T. Gansevoort, Dick de Zeeuw +1 more
The effects of specific intervention in the renin-angiotensin system with the Ang II receptor antagonist losartan and enalapril were investigated and compared these effects to those obtained with ACE inhibition, as this comparison might resolve the question whether or not the effects of ACE inhibition are Ang II related.
American Journal of Kidney DiseasesAdditive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
245 Citations1999Domenico Russo, Antonio Pisani +5 more
This study provides first-time evidence that the combination of CEI and LOS in normotensive patients with IgA nephropathy produces a more profound decrease in proteinuria than either drug.
American Journal of Kidney DiseasesCoadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
243 Citations2001Domenico Russo, Roberto Minutolo +5 more
This study shows that combination therapy with E and LOS has an additive dose-dependent antiproteinuric effect that is likely induced by the drug-related reduction in systemic blood pressure.
Kidney InternationalTargeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
222 Citations1998Harm Peters, Wayne A. Border +1 more
The data suggest that these therapies act through very similar pathways and that, in order to more effectively treat renal fibrosis, these drugs must be combined with other drugs that act by different mechanisms.
Nephron PhysiologyThe Renin-Angiotensin System and Progression of Renal Disease: From Hemodynamics to Cell Biology
214 Citations2002Günter Wolf, Ulrike Butzmann +1 more
This review tries to bridge the classical hemodynamic actions of ANG II in the kidney with the more recently characterized effects of this vasopeptide and suggests the potential of nephroprotective strategies through inhibition of its components.
Nephrology Dialysis TransplantationThe blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
199 Citations1998Hanneke Buter
Kidney InternationalEffects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
186 Citations2003Ruth Campbell, Fabio Sangalli +9 more
Long-term combined ACEi and ARA therapy may be more renoprotective than treatment with each agent alone, and the greater antiproteinuric effect most likely depended on an ACEi-related hemodynamic effect, in addition to glomerular size selectivity amelioration.
Journal of HypertensionSafety of the combination of valsartan and benazepril in patients with chronic renal disease
180 Citations2000Luís M. Ruilope, Jean‐Claude Aldigier +4 more
Investigation of the safety and tolerability of the combination of valsartan and benazepril indicates that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotsin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure.
Kidney InternationalDual renin-angiotensin system blockade at optimal doses for proteinuria
169 Citations2002Gozewijn D. Laverman, Gerjan Navis +3 more
Dose-titration with a renin-angiotensin system blocker, followed by add-on therapy is highly effective in order to reduce proteinuria and the safety of this regimen needs to be addressed in future studies.
Journal of HypertensionAdditive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade
125 Citations2002Paolo Ferrari, Hans‐Peter Marti +2 more
A combination of ACEI and ARB in patients with glomerulonephritis produces a more profound decrease in proteinuria than either drug alone, and this additive antiproteinuric effect is not dependent on changes in blood pressure or creatinine clearance.
Nephrology Dialysis TransplantationRandomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria
85 Citations2002Priscilla Kincaid‐Smith, K. F. Fairley +1 more
The addition of 8 mg of Candesartan in normotensive patients with chronic renal disease and proteinuria receiving an ACEI appeared safe and was not accompanied by adverse effects apart from postural hypotension in three patients and a serum potassium level of 6.3 mmol/l in one.
Kidney InternationalEffects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies
77 Citations2002José Luño, V. Barrio +9 more
Dual blockade of the renin-angiotensin system with ACE inhibitors and AT1 receptor blockers produces a beneficial antiproteinuric effect that could not be explained only by the systemic blood pressure reduction.
American Journal of Kidney DiseasesEffect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels
76 Citations2002Norikuri Komine, Ser Khang +3 more
A reduction in AIIk with ACE inhibitor plus ARB provides a mechanism to understand the synergism of this combination in reducing proteinuria and blood pressure and may have important implications in long-term organ protection in hypertension and renal disease.
American Journal of Kidney DiseasesLate escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease
70 Citations2001Tatsuo Shiigai, Masayoshi Shichiri
Although ACE inhibitors reduce the severity of proteinuria in patients with nondiabetic renal disease, the results show that a proportion of patients escape the antiproteinuric effect and subsequently develop an exacerbation of renal dysfunction.
Current Opinion in Nephrology & HypertensionCombination ACEI and ARB therapy: additional benefit in renoprotection?
65 Citations2002Maarten W. Taal, Barry M. Brenner
American Journal of NephrologyRenoprotective Effect of Small Doses of Losartan and Enalapril in Patients with Primary Glomerulonephritis
46 Citations2002Leszek Tylicki, Przemysław Rutkowski +2 more
It is indicated that even very small doses of losartan and enalapril reduce proteinuria in patients with primary glomerulonephritis and combination of these drugs could cause significantly greater antiproteinuric effect than either of the agents in monotherapy.
PubMedEffect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function.
43 Citations1994Roberto Palla, Vincenzo Panichi +7 more
The antiproteinuric effect of lisinopril is dose-related and may be attributable to some extent to the fall in systemic (and intraglomerular) blood pressure, but it is best attributed to the modification of glomerular sieving function.
Journal of HypertensionReduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition
41 Citations2002Elke D. Berger, Birgit Bader +3 more
Cedesartan promotes a complementary antiproteinuric and a small antihypertensive effect after a treatment period of 8 weeks in patients with chronic glomerulonephritis when given in conjunction with an ACEI.
Kidney InternationalMaximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis
34 Citations2003Carmela Iodice, M Balletta +9 more
Standard doses of either ramipril or irbesartan lead to significant reduction of residual proteinuria and amelioration of the qualitative features suggestive of tubular damage and the enhancement of RAS suppression up to the maximal degree does not improve the antiproteinuric response and is coupled with a decrement of hemoglobin levels.
Clinical TransplantationAntiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage
34 Citations1998Volkmar Lufft, Volker Kliem +8 more
The results show that the lesser the degree of chronic morphological injury, the greater is the antiproteinuric effect of ACE inhibitor therapy after RTx and fosinopril can be administered effectively in a subgroup of proteinuric renal transplant recipients.
Contributions to nephrologyThe Renin-Angiotensin System and Progression of Renal Diseases
30 Citations2001George A. Wolf
The Renin-Angiotensin System and Specific Diseases: AngiotensIn-Converting Enzyme Inhibitors and Progression of Renal Disease - Evidence from Clinical Studies and Relevance for Renal disease.
American Journal of Kidney DiseasesA subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium
28 Citations1999Taha Keilani, Farhad R. Danesh +3 more
A low dose of ramipril can reduce proteinuria to the same extent as an eight-fold higher dose without significantly lowering blood pressure or increasing plasma potassium, which may be advantageous for the treatment of patients at risk for hyperkalemia who require ACE inhibitors.
PubMedPlasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans.
25 Citations1985J. Nussberger, Brunner Db +2 more
Depending on the specificity of the antiserum used, conventional measurement of immunoreactive ANG II underestimates to various degrees the inhibition of angiotensin converting enzyme.
Journal of Cardiovascular Pharmacologyα-Adrenoceptor Blockade in Patients with Mild to Moderate Hypertension
15 Citations1992Lars Romer Krusell, Cramer Christensen +1 more
The results indicate that long-term treatment with doxazosin had no deleterious effect on renal function, but the effects on BP were rather modest, indicating that the individual BP response is probably determined by the degree of fluid retention even if an intact pressure-natriuresis relationship could still be demonstrated during chronic therapy.
SERVAL (Université de Lausanne)Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans
8 Citations1985Nussberger, J., Brunner, D. B. +2 more
Journal of Renal NutritionShort-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: Pilot study
7 Citations2002Leszek Tylicki, Marcin Renke +2 more
Investigating renal and metabolic effects of specific AT-1 receptor blocker-losartan in patients with primary glomerulonephritis concluded that losartan treatment at a small dose of 25 mg daily produces antiproteinuric effect without adverse effects, notably with no decrease of glomerular filtration, and simultaneously induces beneficial changes in purine metabolism.